Ahmed Hena, Shubina-Oleinik Olga, Holt Jeffrey R
Departments of Otolaryngology and Neurology, F.M. Kirby Neurobiology Center Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
J Assoc Res Otolaryngol. 2017 Oct;18(5):649-670. doi: 10.1007/s10162-017-0634-8. Epub 2017 Aug 16.
Gene therapy, or the treatment of human disease using genetic material, for inner ear dysfunction is coming of age. Recent progress in developing gene therapy treatments for genetic hearing loss has demonstrated tantalizing proof-of-principle in animal models. While successful translation of this progress into treatments for humans awaits, there is growing interest from patients, scientists, clinicians, and industry. Nonetheless, it is clear that a number of hurdles remain, and expectations for total restoration of auditory function should remain tempered until these challenges have been overcome. Here, we review progress, prospects, and challenges for gene therapy in the inner ear. We focus on technical aspects, including routes of gene delivery to the inner ear, choice of vectors, promoters, inner ear targets, therapeutic strategies, preliminary success stories, and points to consider for translating of these successes to the clinic.
基因疗法,即使用遗传物质治疗人类疾病,用于内耳功能障碍正逐渐走向成熟。在开发针对遗传性听力损失的基因疗法治疗方面的最新进展已在动物模型中展示了诱人的原理验证。虽然将这一进展成功转化为人类治疗方法仍有待时日,但患者、科学家、临床医生和行业对此的兴趣与日俱增。尽管如此,显然仍存在一些障碍,在这些挑战被克服之前,对听觉功能完全恢复的期望仍应保持适度。在此,我们回顾内耳基因疗法的进展、前景和挑战。我们关注技术方面,包括向内耳递送基因的途径、载体选择、启动子、内耳靶点、治疗策略、初步成功案例以及将这些成功转化至临床时需考虑的要点。